Compositions and methods for treating retroviral infections

• US 20020164321A1
• Filed: 01/16/2002
• Published: 11/07/2002
• Est. Priority Date: 04/17/1998
• Status: Active Grant

• Current Assignee: Surrogate Pharmaceutical Pathways
• Original Assignee: Surrogate Pharmaceutical Pathways
• Inventors: Gallina, Damian J.
• Granted Patent: US 7,157,083 B2
• Time in Patent Office: Days
• US Class Current: 424/94.61
• CPC Class Codes: A61K 2035/124 the cells being hematopoietic, bone marrow derived or blood cells
• CPC Class Codes: A61K 2039/5154 Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
• CPC Class Codes: A61K 2039/5158 Antigen-pulsed cells, e.g. T-cells
• CPC Class Codes: A61K 38/47 acting on glycosyl compounds (3.2), e.g. cellulases, lactases
• CPC Class Codes: A61K 39/12 Viral antigens
• CPC Class Codes: A61K 39/21 Retroviridae, e.g. equine infectious anemia virus
• CPC Class Codes: A61K 39/4614 Monocytes; Macrophages
• CPC Class Codes: A61K 39/4622 Antigen presenting cells
• CPC Class Codes: A61K 39/464838 Viral antigens
• CPC Class Codes: C12N 2740/16034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• CPC Class Codes: C12N 2740/16061 Methods of inactivation or attenuation
• CPC Class Codes: C12N 7/00 Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00

Abstract

The present invention relates to hyaluronidase enzyme methods, vaccines and compositions for treating or preventing pathogenic infections, such as HIV, in a patient. The invention also relates to methods, vaccines and compositions for providing immunity against HIV infection in a patient comprising treating the patient with HIV virus or HIV infected cells that have been treated with hyaluronidase.

Claims

1. A pharmaceutical composition for preventing or treating an HIV infection in a patient comprising a hyaluronidase enzyme.

2. A method for preventing or treating an HIV infection in a patient comprising administering to a patient in need of HV prevention or treatment the pharmaceutical composition of claim 1.

3. A pharmaceutical composition for preventing or treating an HIV infection in a mammal comprising a hyaluronidase treated HIV virus.

4. A pharmaceutical composition according to claim 3 wherein the virus is inactivated or attenuated by heat treatment or chemical treatment.

5. A pharmaceutical composition according to claim 4 wherein the virus is inactivated or attenuated using aldrathiol-2 chemical treatment.

6. A method for preventing or treating an HIV infection in a patient comprising administering to a patient in need of HIV prevention or treatment the pharmaceutical composition of claim 3.

7. A method according to claim 6 wherein the virus is inactivated or attenuated by heat treatment or chemical treatment.

8. A method according to claim 7 wherein the virus is inactivated or attenuated using aldrathiol-2 chemical treatment.

9. A pharmaceutical composition for preventing or treating an HIV infection in a mammal comprising an anti-HIV infection amount of antigen presenting cells that have been sensitized with hyaluronidase treated HIV infected cells.

10. The pharmaceutical composition of claim 9 wherein antigen presenting cells are selected from the group consisting of macrophages and monocytes.

13. A method for preventing or treating an HIV infection in a patient comprising administering to a patient in need of HIV prevention or treatment the pharmaceutical composition of claim 9.

11. A pharmaceutical composition for preventing or treating an HIV infection in a mammal comprising an anti-HIV infection amount of antigen presenting cells that have been sensitized with hyaluronidase treated HIV virus.

12. The pharmaceutical composition of claim 11 wherein the antigen presenting cells are selected from the group consisting of macrophages and monocytes.

14. The method of claim 13 wherein the antigen presenting cells are selected from the group consisting of macrophages and monocytes.

15. A method for preventing or treating an HIV infection in a patient comprising administering to a patient in need of HIV prevention or treatment the pharmaceutical composition of claim 11.

16. The method of claim 15 wherein the antigen presenting cells are selected from the group consisting of macrophages and monocytes.

18. Th e anti-HIV vaccine of claim 17 wherein the HIV virus is inactivated or attenuated by heat treatment or chemical treatment.

19. The anti-HIV vaccine of claim 18 wherein the virus is inactivated or attenuated using aldrathiol-2 chemical treatment.

20. A method of inducing or enhancing an immune response in a patient, the method comprising administering to the patient the anti-HIV vaccine of claim 17.

21. The method of claim 20 wherein the virus is inactivated or attenuated by heat treatment or chemical treatment.

22. The method of claim 21 wherein the virus is inactivated or attenuated using aldrathiol-2 chemical treatment.

17. An anti-HIV vaccine comprising a hyaluronidase treated HIV virus.

23. A method of inducing or enhancing immunity in a patient in need of such treatment in order to initiate responses to otherwise self or host lineage altered cells, antigens or immunogens the method comprising administering to said patient a hyaluronidase enzyme.

24. A pharmaceutical composition used to initiate immune responses to pathogens or pathogen infected cells in a patient in need of such treatment comprising a hyaluronidase enzyme.